LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Koychev, I.; William Deakin, J. F.; El-Deredy, W.; Haenschel, C. (2016)
Languages: English
Types: Article
Subjects: BF

Classified by OpenAIRE into

mesheuropmc: genetic structures
Background\ud Working memory (WM) deficits are a core feature of schizophrenia. Electrophysiological studies suggest that impaired early visual processing may contribute to impaired WM in the visual domain. Abnormal N-methyl-D-aspartate (NMDA) receptor function has been implicated both in WM and in early visual processing deficits in schizophrenia. We investigated whether ketamine, a noncompetitive NMDA antagonist, would replicate in healthy volunteers the WM performance and early visual processing abnormalities we and others have reported in patients with schizophrenia.\ud \ud Methods\ud Forty-four healthy volunteers were randomly assigned to receive intravenous ketamine or placebo. During infusion, the effects of ketamine were recorded using standardized psychiatric scales. Visual evoked potentials (P100 and P300 components) were recorded during performance of a delayed matching to sample task.\ud \ud Results\ud Ketamine induced mild psychosis-like symptoms and impaired WM performance. It also significantly increased the P100 amplitude, while P300 amplitude decreased in a load-dependent manner. Amplitudes of P100 during retrieval correlated with cognitive performance only in the placebo group.\ud \ud Conclusions\ud We confirmed previous studies showing that ketamine reproduces the impairment of WM performance and smaller P300 amplitudes observed in schizophrenia. However, ketamine increased visual P100 amplitude in contrast to our observation of reduced P100 amplitudes in established schizophrenia. The effects of ketamine on WM and P300 are likely to involve impaired NMDA function, as these receptors are implicated in changes of synaptic strength underlying associative learning and memory. Increased P100 amplitude may reflect the secondary disinhibition of cortical glutamate release that occurs after NMDA blockade.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Heinrichs RW (2005): The primacy of cognition in schizophrenia. Am Psychol 60:229-242.
    • 2. Green MF (2006): Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67:e12.
    • 3. Erlenmeyer-Kimling L, Rock D, Roberts SA, Janal M, Kestenbaum C, Cornblatt B, et al. (2000): Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: The New York High-Risk Project. Am J Psychiatry 157:1416-1422.
    • 4. Albus M, Hubmann W, Scherer J, Dreikorn B, Hecht S, Sobizack N, et al. (2002): A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 252:262-267.
    • 5. Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al. (2005): Patient outcomes in schizophrenia II: The impact of cognition. Eur Psychiatry 20:395-402.
    • 6. Milev P, Ho BC, Arndt S, Andreasen NC (2005): Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year followup. Am J Psychiatry 162:495-506.
    • 7. Lawlor-Savage L, Goghari VM (2014): Working memory training in schizophrenia and healthy populations. Behav Sci 4:301-319.
    • 8. Yeap S, Kelly SP, Sehatpour P, Magno E, Garavan H, Thakore JH, et al. (2008): Visual sensory processing deficits in schizophrenia and their relationship to disease state. Eur Arch Psychiatry Clin Neurosci 258:305-316.
    • 9. Butler PD, Martinez A, Foxe JJ, Kim D, Zemon V, Silipo G, et al. (2007): Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain 130:417-430.
    • 10. Koychev I, McMullen K, Lees J, Dadhiwala R, Grayson L, Perry C, et al. (2012): A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A threecenter double-blind placebo-controlled study. Eur Neuropsychopharmacol 22:469-481.
    • 11. Yeap S, Kelly SP, Thakore JH, Foxe JJ (2008): Visual sensory processing deficits in first-episode patients with schizophrenia. Schizophr Res 102:340-343.
    • 12. Yeap S, Kelly SP, Sehatpour P, Magno E, Javitt DC, Garavan H, et al. (2006): Early visual sensory deficits as endophenotypes for schizophrenia: High-density electrical mapping in clinically unaffected first-degree relatives. Arch Gen Psychiatry 63:1180-1188.
    • 13. Koychev I, El-Deredy W, Haenschel C, Deakin JF (2010): Visual information processing deficits as biomarkers of vulnerability to schizophrenia: An event-related potential study in schizotypy. Neuropsychologia 48:2205-2214.
    • 14. Foxe JJ, Simpson GV (2002): Flow of activation from V1 to frontal cortex in humans. A framework for defining “early” visual processing. Exp Brain Res 142:139-150.
    • 15. Fukuda K, Vogel EK (2009): Human variation in overriding attentional capture. J Neurosci 29:8726-8733.
    • 16. Barcelo F, Suwazono S, Knight RT (2000): Prefrontal modulation of visual processing in humans. Nat Neurosci 3:399-403.
    • 17. Zanto TP, Rubens MT, Thangavel A, Gazzaley A (2011): Causal role of the prefrontal cortex in top-down modulation of visual processing and working memory. Nat Neurosci 14:656-661.
    • 18. Jeon YW, Polich J (2003): Meta-analysis of P300 and schizophrenia: Patients, paradigms, and practical implications. Psychophysiology 40: 684-701.
    • 19. Lee SY, Namkoong K, Cho HH, Song DH, An SK (2010): Reduced visual P300 amplitudes in individuals at ultra-high risk for psychosis and first-episode schizophrenia. Neurosci Lett 486:156-160.
    • 20. Qiu YQ, Tang YX, Chan RC, Sun XY, He J (2014): P300 aberration in first-episode schizophrenia patients: A meta-analysis. PloS One 9: e97794.
    • 21. Polich J (2007): Updating P300: An integrative theory of P3a and P3b. Clin Neurophysiol 118:2128-2148.
    • 22. Bledowski C, Prvulovic D, Hoechstetter K, Scherg M, Wibral M, Goebel R, et al. (2004): Localizing P300 generators in visual target and distractor processing: A combined event-related potential and functional magnetic resonance imaging study. J Neurosc 24: 9353-9360.
    • 23. Bledowski C, Cohen Kadosh K, Wibral M, Rahm B, Bittner RA, Hoechstetter K, et al. (2006): Mental chronometry of working memory retrieval: A combined functional magnetic resonance imaging and event-related potentials approach. J Neurosci 26:821-829.
    • 24. Kok A (2001): On the utility of P3 amplitude as a measure of processing capacity. Psychophysiology 38:557-577.
    • 25. Donchin E, Coles MGH (1988): Is the P300 component a manifestation of context updating. Behav Brain Sci, 11, 357-374.
    • 26. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004): Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 70:315-329.
    • 27. Roth WT, Cannon EH (1972): Some features of the auditory evoked response in schizophrenics. Arch Gen Psychiatry 27:466-471.
    • 28. Kim MS, Kang SS, Youn T, Kang DH, Kim JJ, Kwon JS (2003): Neuropsychological correlates of P300 abnormalities in patients with schizophrenia and obsessive-compulsive disorder. Psychiatry Res 123:109-123.
    • 29. Nieman DH, Koelman JH, Linszen DH, Bour LJ, Dingemans PM, Ongerboer de Visser BW (2002): Clinical and neuropsychological correlates of the P300 in schizophrenia. Schizophr Res 55:105-113.
    • 30. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998): Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43:811-816.
    • 31. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
    • 32. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. (1996): NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
    • 33. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004): Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29: 208-218.
    • 34. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000): Ketamine-induced deficits in auditory and visual contextdependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57: 1139-1147.
    • 35. Javitt DC (1996): Glutamate receptors and schizophrenia: Opportunities and caveats. Mol Psychiatry 1:16-17.
    • 36. Moghaddam B, Javitt D (2012): From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37:4-15.
    • 37. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003): NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology 169:215-233.
    • 38. Levin ED, Bettegowda C, Weaver T, Christopher NC (1998): Nicotinedizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav 61: 335-340.
    • 39. Morris RG, Anderson E, Lynch GS, Baudry M (1986): Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319:774-776.
    • 40. Riedel G, Platt B, Micheau J (2003): Glutamate receptor function in learning and memory. Behav Brain Res 140:1-47.
    • 41. Fox K, Sato H, Daw N (1990): The effect of varying stimulus intensity on NMDA-receptor activity in cat visual cortex. J Neurophysiol 64: 1413-1428.
    • 42. Kwon YH, Nelson SB, Toth LJ, Sur M (1992): Effect of stimulus contrast and size on NMDA receptor activity in cat lateral geniculate nucleus. J Neurophysiol 68:182-196.
    • 43. Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D'Souza DC, et al. (2013): The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology 38:2613-2622.
    • 44. Wang M, Yang Y, Wang CJ, Gamo NJ, Jin LE, Mazer JA, et al. (2013): NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 77:736-749.
    • 45. van Loon AM, Fahrenfort JJ, van der Velde B, Lirk PB, Vulink NC, Hollmann MW, et al. (2016): NMDA receptor antagonist ketamine distorts object recognition by reducing feedback to early visual cortex. Cereb Cortex 26:1986-1996.
    • 46. Self MW, Kooijmans RN, Super H, Lamme VA, Roelfsema PR (2012): Different glutamate receptors convey feedforward and recurrent processing in macaque V1. Proc Natl Acad Sci U S A 109: 11031-11036.
    • 47. Knott VJ, Millar AM, McIntosh JF, Shah DK, Fisher DJ, Blais CM, et al. (2011): Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biol Psychol 88:83-93.
    • 48. Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS (2009): Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. Int J Neuropsychopharmacol 12:823-832.
    • 49. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN (2000): The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22:293-302.
    • 50. Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, et al. (2012): Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry 71: 969-977.
    • 51. Musso F, Brinkmeyer J, Ecker D, London MK, Thieme G, Warbrick T, et al. (2011): Ketamine effects on brain function-simultaneous fMRI/ EEG during a visual oddball task. Neuroimage 58:508-525.
    • 52. Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH (2009): Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. Int J Neuropsychopharmacol 12:357-370.
    • 53. Ahn KH, Youn T, Cho SS, Ha TH, Ha KS, Kim MS, et al. (2003): N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: Event-related potential study of late stage of working memory process. Prog Neuropsychopharmacol Biol Psychiatry 27: 993-999.
    • 54. Raine A (1991): The SPQ: A scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 17:555-564.
    • 55. Koychev I, McMullen K, Lees J, Dadhiwala R, Grayson L, Perry C, et al. (2012): A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A threecenter double-blind placebo-controlled study. Eur Neuropsychopharmacol 22:469-481.
    • 56. Nelson HE (1982): National Adult Reading Test (NART): For the Assessment of Premorbid Intelligence in Patients with Dementia: Test Manual. Windsor, UK: NFER-Nelson.
    • 57. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, et al. (2013): Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage 64:75-90.
    • 58. Absalom AR, Lee M, Menon DK, Sharar SR, De Smet T, Halliday J, et al. (2007): Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers. Br J Anaesth 98:615-623.
    • 59. Haenschel C, Bittner RA, Haertling F, Rotarska-Jagiela A, Maurer K, Singer W, et al. (2007): Contribution of impaired early-stage visual processing to working memory dysfunction in adolescents with schizophrenia: A study with event-related potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 64:1229-1240.
    • 60. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. (1998): Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11:125-136.
    • 61. Overall JE, Gorham DR (1962): The brief psychiatric rating scale. Psychol Rep 10:799-812.
    • 62. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, et al. (2005): Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179:303-309.
    • 63. Lalor EC, Yeap S, Reilly RB, Pearlmutter BA, Foxe JJ (2008): Dissecting the cellular contributions to early visual sensory processing deficits in schizophrenia using the VESPA evoked response. Schizophr Res 98:256-264.
    • 64. Moghaddam B, Adams B, Verma A, Daly D (1997): Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
    • 65. Moran RJ, Jones MW, Blockeel AJ, Adams RA, Stephan KE, Friston KJ (2015): Losing control under ketamine: Suppressed corticohippocampal drive following acute ketamine in rats. Neuropsychopharmacology 40:268-277.
    • 66. Anticevic A, Cole MW, Repovs G, Savic A, Driesen NR, Yang G, et al. (2013): Connectivity, pharmacology, and computation: Toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry 4:169.
    • 67. Meuwese JD, van Loon AM, Scholte HS, Lirk PB, Vulink NC, Hollmann MW, et al. (2013): NMDA receptor antagonist ketamine impairs feature integration in visual perception. PloS One 8:e79326.
    • 68. Kurylo DD, Gazes Y (2008): Effects of ketamine on perceptual grouping in rats. Physiol Behav 95:152-156.
    • 69. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001): Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467.
    • 70. Luck SJ, Hillyard SA, Mouloua M, Woldorff MG, Clark VP, Hawkins HL (1994): Effects of spatial cuing on luminance detectability: Psychophysical and electrophysiological evidence for early selection. J Exp Psychol Hum Percept Perform 20:887-904.
    • 71. Corlett PR, Honey GD, Krystal JH, Fletcher PC (2011): Glutamatergic model psychoses: Prediction error, learning, and inference. Neuropsychopharmacology 36:294-315.
    • 72. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997): Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-811.
    • 73. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997): Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25-38.
    • 74. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA (2001): Sequential regional cerebral blood flow brain scans using PET with H2 (15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 25:165-172.
    • 75. Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ, et al. (2012): NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A 109:16720-16725.
    • 76. Anticevic A, Repovs G, Shulman GL, Barch DM (2010): When less is more: TPJ and default network deactivation during encoding predicts working memory performance. Neuroimage 49:2638-2648.
    • 77. Bittner RA, Linden DE, Roebroeck A, Hartling F, Rotarska-Jagiela A, Maurer K, et al. (2015): The when and where of working memory dysfunction in early-onset schizophrenia-a functional magnetic resonance imaging study. Cereb Cortex 25:2494-2506.
    • 78. Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, et al. (2015): N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry 77:569-580.
    • 79. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM (2008): Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65:154-164.
    • 80. Hong LE, Summerfelt A, Buchanan RW, O'Donnell P, Thaker GK, Weiler MA, et al. (2010): Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 35:632-640.
    • 81. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D, et al. (2009): N-methyl-d-aspartic acid receptor antagonistinduced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 158:705-712.
    • 82. Langsjo JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, et al. (2003): Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99:614-623.
    • 83. Langsjo JW, Maksimow A, Salmi E, Kaisti K, Aalto S, Oikonen V, et al. (2005): S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 103:258-268.
    • 84. Noh HJ, Bae YM, Park SH, Kim JG, Kim B, Kim YS, et al. (2009): The vasodilatory effect of ketamine is independent of the N-methylD-aspartate receptor: Lack of functional N-methyl-D-aspartate receptors in rat mesenteric artery smooth muscle. Eur J Anaesthesiol 26:676-682.
    • 85. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE (2013): Glutamate in schizophrenia: A focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull 39: 120-129.
    • 86. Mathalon DH, Ahn KH, Perry EB Jr, Cho HS, Roach BJ, Blais RK, et al. (2014): Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans. Front Psychiatry 5:3.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
    59
    59%
  • No similar publications.

Share - Bookmark

Download from

Funded by projects

  • WT

Cite this article